CClinicalTrials.gg
CompletedNCT06827171LLLTUpdated Aug 19, 2025

Impact of LLL and Aerobic Exercise on Peripheral Arterial Outcomes in Patients With Type 2 Diabetes

A Phase 2 interventional study of aerobic exercise + low-level laser therapy and Aerobic exercise in Type 2 Diabetes Mellitus (T2DM), sponsored by Nouran Hesham Slama Younis. Completed at 1 site in Egypt. Open to participants aged 55 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Nouran Hesham Slama Younis · Phase 2, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 3 months ago, and no results have been posted to the registry.
Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
55 Years to 65 Years
Sex
All
01

Study summary

Diabetes is one of the fastest-growing diseases worldwide, It has Devastating macrovascular complications (cardiovascular disease) and microvascular complications (such as diabetic kidney disease, diabetic retinopathy, and neuropathy) In Egypt, factors in patients that affect diabetic control include the patient's education and occupation and smoking status. Physical exercise is important for diabetes control. Metformin and investigation availability have a positive association with diabetes control.

Diabetes mellitus increases the risk and accelerates the course of peripheral artery disease, making patients more susceptible to ischemic events and infections and delaying tissue healing. The current understanding of pathogenic mechanisms is mainly based on the negative influence of diabetes mellitus on atherosclerotic disease and inflammation (Fadini et al., 2020).) An early diagnosis of peripheral arterial diseases PAD and correctly identifying patients with Chronic limb-threatening ischemia CLTI are crucial in patients with diabetes to improve outcomes.

Several treatment strategies can be subdivided into lifestyle modification, medical management, endovascular therapies, and surgical interventions for the treatment of PAD.

Exercise training improves walking ability, distances, physical function, and vitality. Physical activity by supervised exercise is recommended in first-line therapy for intermittent claudication by SVS, ESVS, and AHA (Treat-Jacobson et al., 219) More specifically, a supervised exercise program consists of walking a minimum of three times per week (30-60 min/session) for at least 12 weeks Therapeutic laser treatment, also known as low-level laser therapy (LLLT), offers numerous benefits. It is non-surgical, promotes tissue healing, and reduces edema, inflammation, and pain.

Read the detailed description

The participants will be submitted into two equal groups in numbers:

Group A (Study group) n=20 will receive a low-level laser (scanning laser) combined with an aerobic exercise program for 12 weeks (3 sessions/ week).

Group B (control group) n=20: Who will receive aerobic exercise for 12 weeks (3sessions/week) All patients with their prescribed medications (hypoglycemic, antiplatelet, anticoagulants, antihypertensive, vasodilators, analgesics)

02

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Peripheral artery Disease
  • Low level laser
  • Aerobic exercise
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's enrollment of 40 is below the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

This is the only study on the registry with Nouran Hesham Slama Younis as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Their ages will range from 55- 65 years, for both genders.
  • Body Mass Index of 25-29.9kg/m2.
  • Glycated hemoglobin (HbA1c) from 7 to 9 %.
  • The patient has suffered from diabetes for more than 5 years.
  • Patient with mild to moderate PAD on Rutherford classification stages (1-3)

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of hypo-hyperglycemic coma.
  2. Uncontrolled cardiovascular complications, and ischemic heart disease.
  3. Photosensitivity, Malignancy, Anemia, Hemorrhagic diseases (contraindication to laser)
  4. Deep venous thrombosis, acute thromboses.
  5. Cerebrovascular disease.
  6. Patients with Monckeberg sclerosis.
  7. Patient with resting pain critical limb ischemia, diabetic foot, and peripheral edema, asymptomatic PAD, Diabetic neuropathy.
  8. Patient with minor/ or major amputations.
  9. A patient with positive smoking
05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Study group A: Aerobic exercise+ low-level Laser therapy

    (Study group A): It will receive a low-level laser (scanning laser) on the course of the posterior tibial and anterior tibial artery combined with an aerobic exercise program for peripheral artery disorder for 12 weeks (3 sessions/ week).

    Combination Product: aerobic exercise + low-level laser therapy · Other: Aerobic exercise

  • Experimental
    Control group B: Aerobic Exercise group B

    group B: They will receive aerobic exercise for 12 weeks. aerobic exercise program for peripheral arterial disorders and intermittent claudication.

    Other: Aerobic exercise

Interventions

  • Combination productaerobic exercise + low-level laser therapy

    low- level laser parameters: The wavelength: 808 +/- 5nm The power: output is 450 Mw Type of beam: red laser beam. Beam Divergent \>,025 rad+/- ,005rad Nominal Distance of Sight hazard \>8m The duration: is 20 min for each artery. Treatment period: 3 times/week for 3 months.

  • OtherAerobic exercise

    Aerobic exercise Frequency = 3sessions/week duration: 10 min warm up and 10 min cool down/ 30 min stance phase Intensity: moderate intensity initiating with 50% HR max to end 75% HR max

06

What researchers measure

Primary outcomes

  1. body mass index

    Body mass index (Kg/M\^2): by dividing the weight by kilogram over Height by meter square.

    Time frame: 3 month

  2. peak systolic velocities (PSV)

    Duplex ultrasonography of the lower extremity arteries, from common femoral to pedal arteries is used to measure PSV * Peak systolic velocities (PSV) were recorded in meters per second (Ugwu et al., 2021). * The normal peak systolic velocity (PSV) in peripheral lower limb arteries varies from 45-180 cm/s (Abdelrahman, 2010). Severe arterial disease manifests as a PSV over 200 cm/s, monophasic waveform, and spectral broadening of the Doppler waveform.

    Time frame: 3 months

  3. Ankle-Brachial Index (ABI) %

    • Ankle-Brachial Index (ABI) is a ratio of the highest ankle systolic blood pressure obtained in the anterior tibial/ dorsalis pedis or posterior tibial artery to that of the highest brachial systolic pressure. An ABI \< 0.9 was diagnostic of PAD and values were stratified according to severity as: * 0.7-0.89 = mild arterial obstruction. * 0.5-0.69 = moderate arterial obstruction. * ≤ 0.5 = severe arterial obstruction.

    Time frame: 3 months

  4. The visual analog scale (VAS) questionnaire for pain

    The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain." Delgado etal., 2018). * no pain (0-4 mm) * mild pain(5-44 mm) * moderate pain (45-74 mm) * severe pain (75-100 mm). (Weigl K et al., 2021)

    Time frame: 3 months

  5. The Edinburgh Claudication Questionnaire (ECQ)

    The Edinburgh Claudication Questionnaire (ECQ) Definition of positive classification requires all of the following responses: \\Yes" to (1), \\No" to (2), \\Yes" to (3), Grade 1 \\No" to (4), and Grade 2 \\Yes" to (4). If these criteria are met, a typical claudicant is one who indicates the pain is in the calf, regardless of whether the pain is also marked at other sites; a diagnosis of atypical claudication is made when the pain is marked in the thigh or buttock, in the absence of any calf pain. Subjects should not be diagnosed with claudication if the pain is indicated in the hamstrings, feet, shins, and joints, or radiates in the absence of any calf pain

    Time frame: 3 months

Secondary outcomes

  1. The initial claudication distance and The absolute claudication distance (meters)

    The initial claudication distance (ICD), or pain-free walking distance; is the distance walked at the onset of claudication pain The absolute claudication distance (ACD), or maximal walking distance at which claudication pain becomes so severe that the patient is forced to stop (Jongert et al., 2003)

    Time frame: 3 months

  2. Maximum oxygen consumption Vo^2 max ((ml/kg/min))

    depend on Modified Bruce protocol with the treadmill. Modified Bruce protocol, the first stage at 1.7mph and 0% grade second stage at 1.7 mph 5% grade, and the third stage at 1.7 mph and 10% grade. The test score is the time taken on the test, in minutes. This can also be converted to an estimated VO2 max score using the calculator below and the following formulas, where the value "T" is the total time completed (expressed in minutes and fractions of a minute e.g. 9 minutes 25 seconds = 9.25 minutes). Men : VO2max (ml/kg/min) = 14.76 -(1.379 × T) + (0.451 × T²)-(0.012 × T³) Women: VO2max (ml/kg/min) = 4.38x T -3.9 (ACSM, 2023)

    Time frame: 3 months

07

Study locations

1 site
  • Cairo University
    Cairo, Egypt 12613, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06827171
Lead sponsor
Nouran Hesham Slama Younis
Responsible party
Nouran Hesham Slama Younis (Clinical investigator, police hospital, Egypt, Cairo University) — Sponsor-investigator
First posted
Feb 14, 2025
Start date
Feb 20, 2025
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Last update
Aug 19, 2025

Study contacts

Nesreen Gh EL NAHAS, doctor
principal investigator · head of physical therapy department for internal medicine, Cairo university.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion